Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Living Cell faces slower road to commercialisation

Living Cell faces slower road to commercialisation after trial needs more

to editor
By Rebecca Howard

Nov. 10 (BusinessDesk) - ASX-listed Kiwi biotech firm Living Cell Technologies won't seek provisional consent for its treatment for Parkinson's disease after the latest trial did not show a "statistically significant difference" between people who received the treatment and those who didn't.

The Melbourne-based company halted trading of its shares yesterday ahead of the trial's results, which it was hoping would give it the all-clear to pursue commercial sales of its treatment as early as next year.

"More data analysis and input from our advisers is required but at this time we cannot proceed with a regulatory application," chief executive Ken Taylor said in a statement to the ASX.

Living Cell developed the NTCELL treatment for Parkinson’s disease using choroid plexus brain cells from neonatal pigs, which are implanted into a damaged site in the brain and then function as a “neurochemical factory” producing factors that promote new central nervous system growth and repair disease-induced nerve degeneration.

The cell therapy had shown potential in early trials as a disease-modifying agent in Parkinson’s disease. The latest study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient subgroup. The biotech firm's Phase IIb clinical trial was completed in April and it had been waiting for the results to be unblinded,

There were three groups of six patients and two patients from each group had sham surgery with no NTCELL implanted, to act as a control. The remaining patients received different numbers of microcapsules of NTCELL on each side of the brain.

While no product or procedure adverse events occurred and there is no evidence of xenogeneic infection in patients and their partners "we are disappointed that the efficacy primary endpoint has not been met," said Taylor.

Principal investigator Barry Snow at Auckland City Hospital said the next step is to analyse the data in depth and continue to monitor patients in accord with the study extension protocol, particularly for the efficacy movements at longer time points.

The ASX-listed shares last traded at 20.5 Australian cents and have risen 130 percent so far this year.

(BusinessDesk)

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 




Barfoot & Thompson: Auckland Rental Prices Inch Up Again, But Upward Trend Could Ease In Coming Months

Data from nearly 16,000 rental properties managed by real estate agency Barfoot & Thompson shows Auckland’s average weekly rent rose by $6.12 (or 1 percent) during the second quarter... More>>

ComCom: Draft Report Says Regulatory System Favours Established Building Products
The Commerce Commission’s draft report into competition in the residential building supplies industry has identified two main factors negatively impacting competition... More>>

Statistics: Annual Wage Inflation Rises To 3.4 Percent
Wage inflation, measured by the labour cost index (LCI), was 3.4 percent in the year ended June 2022, while average ordinary time hourly earnings rose 6.4 percent, Stats NZ said today... More>>

ALSO:

APEC: Region’s Growth To Slow Amid Uncertainties And Crises
Economic growth in the APEC region is expected to slow this year amid soaring inflation, a protracted war in Ukraine and heightened uncertainties, on top of the continuing impact of the pandemic and virus mutations that are draining resources, according to a new report by the APEC Policy Support Unit... More>>


Financial Markets Authority: Survey Sheds Light On New Zealanders’ Experiences With Financial Sector
Most New Zealanders are confident in their ability to make financial decisions, but only one-fifth say they are in a secure financial position... More>>


ASB: Latest Trade Disruption Report: Low Export Demand And High Import Prices Look Set To Continue

After a strong initial recovery from the effects of COVID-19 in 2021, New Zealand is likely to feel the impact of slowing global trade well into 2023, according to ASB’s latest Trade Disruption economic report... More>>